Who is sponsoring NCT04156906?

NCT04156906 is sponsored by Children's Hospital of Philadelphia.

What drugs are being tested in NCT04156906?

Interventions in NCT04156906: D+ RH genotype matched red cell units for transfusion.

What condition does NCT04156906 study?

NCT04156906 studies Sickle Cell Disease, Anti-D Antibodies.

Is NCT04156906 still recruiting?

NCT04156906 is currently completed. Last updated 2 May 2025.

Are results published for NCT04156906?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-02 · How we verify

NCT04156906

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RHD Genotype Matched Red Cells for Anti-D

Completed EARLY_PHASE1 Results posted Last updated 2 May 2025

What this trial tests

EARLY_PHASE1 trial testing D+ RH genotype matched red cell units for transfusion in Sickle Cell Disease in 5 participants. Completed in 4 October 2024.

Timeline

8 July 2020

Primary endpoint
4 March 2024

4 October 2024

Quick facts

Lead sponsor	Children's Hospital of Philadelphia
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	8 July 2020
Primary completion	4 March 2024
Estimated completion	4 October 2024
Sites	1 location across United States

Drugs / interventions tested

D+ RH genotype matched red cell units for transfusion — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →
Anti-D Antibodies — all drugs for Anti-D Antibodies →

Sponsor

Children's Hospital of Philadelphia

Who can join

8 and older, any sex, with Sickle Cell Disease or Anti-D Antibodies. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Anti-D Recurrence Primary · Through study completion and follow-up phase, an average of 10 months per participant

To determine safety of providing RH genotype match red cells to patients with a history of anti-D, we observed if anti-D reappearance occurred or evidence of hemolysis of transfused red cells.

Group	Value	95% CI
D+ RH Genotype Matched Red Blood Cell Transfusion	0
D+ RH Genotype Matched Red Blood Cell Transfusion	5

Sponsor's own description

This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell) units.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Genotyped RhD+ red cells for D-positive patients with sickle cell disease with conventional RHD and unexpected anti-D.
Chou ST, Mewha J, Friedman DF, Lazariu V, et al · · 2024 · cited 4× · PMID 39172743 · DOI 10.1182/blood.2024025602

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Children's Hospital of Philadelphia trials

Trials by the same sponsor.

NCT07023380 — EoE Food Test Pilot Study · NA · not yet recruiting
NCT06693752 — CEUS Evaluation of Hydrocephalus in Neonates and Infants · Phase 2 · recruiting
NCT07425691 — SPACE for Youth With Chronic Pain · recruiting
NCT07444528 — Upper Airway Ultrasound to Predict Difficult Laryngoscopy in Neonates and Infants · enrolling by invitation
NCT07321327 — Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2 · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04156906 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Philadelphia
Last refreshed: 2 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing